The protective effects of the hormones androstenediol (androstene-3P, 17/?,-diol; AED) and dehydroepiandrosterone (5-androsten-3P-ol-17-one; DHEA) on the pathophysiology of two lethal bacterial infections and endotoxin shock were examined. The infections included a gram-positive organism (Enterococcus faecalis) and a gram-negative organism (Pseudomonas aeruginosa). Both hormones protected mice from the lethal bacterial infections and from lipopolysaccharide (LPS) challenge. Treatment of animals lethally infected with I? aeruginosa with DHEA resulted in a 43% protection whereas treatment with AED gave a 67% protection. Both hormones also protected completely animals infected with an LD50 dose of E. faecalis. Similarly, the 88% mortality rate seen in LPS challenge was reduced to 17% and 8.5%, by treatment with DHEA and AED, respectively. The protective influences of both steroids were shown not to be directly antibacterial, but primarily an indirect antitoxin reaction. DHEA appears to mediate its protective effect by a mechanism that blocks the toxin-induced production of pathopysiological levels of tumour necrosis factor-a (TNF-a) and interleukin-1. AED usually had greater protective effects than DHEA; however, the AED effect was independent of TNF-a suppression, both in vivo and in vitro.
Introduction
Androstenediol (androstene-3P 17P-diol; AED) and dehydroepiandrosterone (5-androsten-3P-01-17-one; DHEA) have been shown to exert an influence upon the immune system that results in a generalised and nonspecific increase of host resistance against infections. Several models of acute virus infection have been used to determine the influence of both AED and DHEA on the pathophysiology of infection. The results of these studies have illustrated protection against six different human RNA and DNA viruses including West Nile, Sindbis and Semliki Forest [ 1-31, coxsackievirus B4, herpes simplex type 2 [4-61 and influenza Avirus [7] . These studies led to the conclusion that administration of AED or DHEA up-regulated host immunity and reduced the virulence of both RNA or DNA viruses that are lethal by widely different pathogenic mechanisms [8].
Because of their immunoregulatory influences, it was pertinent to examine the effects of these hormones on two models of lethal bacterial infection. In particular, the aim was to investigate the influence of AED and DHEA on both a gram-positive infection (Enterococcus faecalis) and a gram-negative infection (Pseudornonas aeruginosa). These two organisms are known for their resistance to antibiotics and high incidence of infection in diabetics and cancer patients [9, 101. Therefore, the development of novel antibacterial strategies may provide new approaches to treating opportunist infections caused by resistant organisms.
Although gram-positive and gram-negative bacteria differ in their structural proteins and respective toxins, certain aspects of the pathophysiology of disease are comparable [ 10-131. During the course of gram-negative infections, the release of endotoxin (lipopolysaccharide, LPS) can induce intense pathophysiological alterations [lo, 14, 151 . One of the major responses to LPS in vivo is the rapid production and secretion of pro-inflammatory cytokines, including tumour necrosis factor-a (TNF-a) [ 16-181 and interleukin-1 a [ 19, 201. Although gram-positive bacteria lack endotoxin, other constituents of their cell wall and exotoxins can induce TNF-a and ILla production [2 1, 221. The elevated production of these potent proinflammatory cytokines has profound influences on the physiology of the host and is responsible for many of the symptoms associated with bacterial infection, including the characteristic high fever and cachexia. Overactivation of this cytokine network can not only damage tissues of the host but can ultimately lead to death [ 181. LPS toxicity can be reduced by administration of potent immunosuppressive glucocorticoids that inhibit the production of TNF and other cytokines if given before LPS challenge [ 17, 231. However, the immunosuppressive influences of glucocorticoids leave the host susceptible to infection by other opportunist agents.
Materials and methods

Preparation of steroid solutions
DHEA was obtained from Steraloids, (Wilton, NH, USA). AED was purchased from Sigma [2, 6, 241. Unless otherwise stated these steroids were dissolved in DMS0:EtOH (1: 1) as the vehicle.
Mice
CD-1 female mice (Charles River, London) were 2 1 days old upon arrival and were maintained in the animal facility until the age of 4-6 months. ICR outbred male mice (Harland Sprague Dawley, Indianapolis, IN, USA) were 8 weeks old and underwent adaptation for no less than 1 week before being used. Animal facilities are routinely maintained at 24°C with water and food ad libitum.
Bacteria I? aeruginosa. The virulence of the I? aeruginosa strain for mice had been determined previously [25] . A bacterial suspension containing 2 X 1 O9 cfU/ml was kept frozen at -70°C in 1-ml tubes until use. Mice (6 months old) were inoculated intraperitoneally (i.p.) with 0.2 ml containing 2X lo7 cfb. AED or DHEA was injected subcutaneously (s.c.) 2 h before bacterial inoculation.
E. faecalis. E. faecalis X1515.OGlRF, a plasmidbearing strain, which is virulent for mice was grown on blood agar. This strain was a generous gift from Dr H. Dalton (Medical College of Virginia, Richmond, VA, USA). The number of cfU was determined by spectrophotometry by reference to standards verified by subculture and plate counts. A dose of 1 X 10" c h / animal in 0.5 ml of saline was used i.p. for challenge experiments.
LPS challenge
A lethal dose (800 pglmouse) of LPS (Lipopolysaccharide W, Escherichia coli 055:B5; Difco Labora-tories, Detroit, MI, USA), was diluted in pyrogen-free saline and injected into CD-1 mice i.p. DHEA (80 mg) was dissolved in 0.8 ml of absolute alcohol and then diluted with inactivated rabbit serum (10%) in saline (RSSP) to give a final volume of 16 ml. Each mouse received 2 m g [24] . AED (30 mg) was dissolved in 1.2 ml of absolute alcohol and diluted to a final volume of 15 ml with RSSP. Each mouse was given 0.4 mg. Control mice were inoculated with the vehicle only at the same times. Mice were observed daily for mortality for 14 days.
TNF-a assay
To determine TNF-a production, mice were inoculated with LPS (100 pg/mouse) i.p. 20 min after the S.C. injection of DHEA or AED. Mice were bled 60 min after LPS treatment. Blood was collected into serum separator tubes (Becton-Dickinson). Serum was separated and frozen at -70°C until hrther processing.
In-vitro experiments
The procedure of Kruisbeek [26] was used for the proliferation of spleen cells from three of four BALB/c or C57BL/6J mice. Briefly, the mitogens concanavalin A (ConA) and Escherichia coli LPS were diluted in phosphate-buffered saline (PBS) with fetal calf serum 1% to a concentration of 1.0 mg/ml. The optimal working concentration of ConA was found to be 2.5 pg/ml while that of LPS was 5.0 pg/ml. The viability of spleen cells was determined by exclusion of trypan blue 0.4% after a haemacytometer count had been made. Unfractionated lymphocytes were maintained in RPMI 1640 containing FCS lo%, 200 p~ Lglutamhe, 20 mM Hepes, penicillin 2.5 U/ml, streptomycin 2.5 pg/ml and 5.0X M 2-mercaptoethanol. For proliferation studies, 0.1-ml volumes of the mixed cell suspension at a concentration of 5.0 X lo6 cells/ml were cultured in 96-well tissue culture plates. For cytokine assays, 1.0-ml volumes of this same cell suspension were cultured in 24-well tissue culture plates. For each study unfractionated spleen cells were incubated at 37°C in a CO2 5% incubator. Murine macrophages RAW 264.7 (Ig and complement receptor positive), were obtained from the American Type Culture Collection (ATCC).
TNF-a bioactivity in serum was determined with A-9 cells (ATCC, Rockville, MO, USA). Briefly, 3X104 A-9 cells were seeded in wells of microtitration plates and allowed to adhere overnight. Wells were treated with serial dilutions of the sample serum followed by addition of cycloheximide 25 pg/ml. After incubation for 8-10 h, the cells were washed and the number of surviving cells was determined by uptake of neutral red. The mouse T-cell clone D10.G4.1 was used for measurement of soluble IL-1 and was maintained in complete Clicks-5 medium containing ConA 2.5 pg/ml. For a positive control, recombinant murine IL-1 was purchased from R&D, Minneapolis, USA). In addition, representative results obtained from this assay were verified by repeat measurement with an IL-1 -specific ELISA obtained from Genzyme (Cambridge, MA., USA).
Statistical analysis
Data are presented as means and SD and were analysed for significance by analysis of variance (ANOVA) or by Student's t test, as stated.
Results
The effects of AED and DHEA on P aeruginosa infection The protective effects of AED and DHEA towards a dose of 2 X lo7 cfu of I? aeruginosa that causes 100% mortality in the strain of mouse used [25] is illustrated in Table 1 . Experiments 1 and 2 show that DHEA treatment at a dose of 20 mg, 2 h before l? aeruginosa injection protected 50% and 38.5% of the animals, respectively, in two separate experiments.
A combination of the results of both experiments shows that 43% of the animals treated with DHEA Similarly, 2 mg of AED resulted in 71.5% and 62.5% protection in two separate experiments. A combination of the results of both experiments shows that AED protected 67% of animals infected with a lethal dose of I? aeruginosa.
The results show that treatment with either AED or DHEA in vivo significantly (p<O.O5) increased the survival of mice given a lethal dose. Furthermore, AED is more effective than DHEA against I? aeruginosa infection as is evident from the level of protection and the use of one-tenth the dose of DHEA.
The effects of AED and DHEA on E. faecalis infection
To establish that the effects of these hormones were not limited to gram-negative bacterial infections, the effects of both hormones were tested on a lethal challenge with E. faecalis. Treatment of mice infected with this bacterium with a single dose of either AED (8 mg) or DHEA (25 mg) 2 h before bacterial challenge protected all animals, whereas 57% of untreated animals died (p<O.O5) ( Fig. 1) . Thus, these data show that both AED and DHEA have a similar protective effect against a lethal E. faecalis infection. The absence of direct antibacterial effects of AED or DHEA at concentrations ranging from 5 X M to 5X10-* M was determined in veal infusion broth cultures 24 h after inoculation. Changes in growth rate were determined by OD340 measurements. Untreated E. faecalis control cultures had a mean OD340 reading of 0.8565 (SD 0.01), while the averages of all DHEAand AED-treated cultures were 0.8353 (SD 0.02) and 0.834 (SD 0.02) respectively (10 samples were used for each group). Thus, neither AED nor DHEA altered the growth rate of the bacterium at any of the concentrations tested.
AED against lethal infection in mice
Endotoxic challenge and TNF-a levels: protective effects of AED and DHEA
In all, 88% of untreated animals inoculated with 800 pg of LPS per mouse died within 72 h (Fig. 2) . However, pretreatment with DHEA (2 mg) given 1 h before the LPS reduced mortality from 88% to 17%. AED treatment (0.4 mg) reduced LPS-induced mortality from 88% to 8.5%. Even though both drugs were found to be effective in protecting from LPS toxicity, AED at one-fifth the dose of DHEA was again more protective.
Because LPS is known to mediate an increase in TNF-a levels, the study investigated whether the protective effects of AED or DHEA observed were caused by suppression of LPS-mediated TNF-a secretion in vivo was examined. Fig. 3 shows that 100 pg of LPS induced high TNF-a levels in vivo, resulting in an increase from a mean of 1028.0 (SD 90) pg/ml in control mice to a mean of 7366. resulted in a marked reduction of TNF-a levels of around 50%. However, the lower dose of AED which protected mice in vivo from lethal challenge, was ineffective in reducing TNF-a levels in this system.
These observations demonstrate that the protective effect of AED and DHEA against bacterial and endotoxin challenge are distinct from each other and that this protective effect of AED is not mediated by the reduction of TNF-a.
Influence of AED and DHEa in vitro
Because of the ability of DHEA and AED to protect mice against LPS toxicity, the following experiments were designed to examine their roles in vitro. First, the ability of both steroids to modifL proliferation of LPSstimulated splenocyte cultures was assessed. C57BL/6 murine spleen cell cultures stimulated by LPS 5 pg/ml were treated with concentrations of DHEA ranging from 5.0X M to 5.0X M. DHEA suppressed proliferation as determined by a reduced [3H] thymidine uptake after culture for 24 h (Table 2), e.g., at
5.0X
M, DHEA suppressed proliferation by 2 1.5% compared with LPS-stimulated controls. In contrast, AED at the same concentrations had no effect on splenocyte proliferation. Subsequent experiments were designed to determine whether the observed ability of DHEA to suppress TNF-a and IL-1 production in vivo could be modelled in vitro with an LPS-sensitive macrophage cell line. Again, treatment of murine macrophages (RAW 264.7) stimulated by LPS 50 ng/ml with DHEA suppressed the production of both TNF-a and IL-1 (Tables 3 and  4) . AED had no effect on the production of either proinflammatory cytokine. These in-vitro measures correlated with those from the in-vivo experiments and further revealed the dichotomy between the function of AED and DHEA even though each steroid hormone protected mice from the lethal effect of bacterial infection and LPS toxicity.
Table3. Effects of DHEA and AED on the in-vitro production of TNF-a by RAW264.7 murine macrophages stimulated by LPS Mean (SD) TNF-a (pg/ml) secreted by Concentration macrophages exposed to of steroid (moles/L) DHEA This study demonstrated the potential of the naturally occurring steroid hormones AED and DHEA to protect against lethal bacterial infections in a rodent model. Both hormones were effective in preventing death from a lethal challenge by either the gram-negative organism 19 aeruginosa, or the gram-positive E. faecalis. Although a precise mechanism of action has not been defined for AED and DHEA, neither steroid appeared to have direct antibacterial effects, because the growth characteristics of P aeruginosa, and E. faecalis were not altered in an in-vitro assay. Furthermore, because both 19 aeruginosa and E. faecalis exert their virulence by their toxigenic actions [9, 10, 131, the protective effects of these hormones may be mediated, at least in part, by their ability to modulate the actions of virulence factors associated with each organism.
Injection of LPS i.p. has been reported to stimulate the release of many cytokines, including TNF-a and IL-la, within 45 min. Zuckerman et al. [27] reported that maximal serum TNF-a was detected within 1 h of injection; elevated levels returned to baseline with 3-4 h. The peripheral inflammatory response elicited as a result of the increase in these cytokines results in activation of a central response involving the hypothalamic-pituitary-adrenal (HPA) axis which among others leads to changes in thermo-regulation, and an overactivation of the immune response reported that following inoculation of CD-1 mice with 100 pg of LPS, plasma corticosterone levels increased almost eight-fold from 94ng/ml to 740ng/ml. Activation of the HPA axis may function as feedback control over the production of pro-inflammatory cytokines because the principal product of HPA activation, namely adrenal glucocorticoids, suppresses production of TNF-a and IL-la by macrophages [3 1, 321.
This was supported by the observation that the decrease in TNF-a 3-4 h after LPS injection correlated with the appearance of significant amounts of endogenous serum corticosterone [27] . Furthermore, treatment of LPS-stimulated mice with the glucocorticoid receptor antagonist RU486 blocked corticosterone function and led to augmented production of serum TNF-a [33] . TNF-a is considered to be a major proximal mediator of septic shock [16, 23, [34] [35] [36] [37] The results reported here support the premise that DHEA protects mice from bacterial infection and LPS toxicity by blocking the toxin-induced production of TNF-a in view of the data showing suppression of serum TNF-a levels in vivu and suppression of TNF-a production from cultured macrophages in vitru. The results of this study also show that significantly lower doses of AED had a greater protective effect than DHEA against in-vivo challenge with I? aeruginosa, E. faecalis or LPS. However, AED did not reduce the levels of TNF-a either in vivu or in vitru. On the basis of these observations, it is apparent that the protective actions of these two hormones operate by different mechanisms, with that if AED being independent of TNF-a production. DHEA has been reported to function as a weak glucocorticoid because it suppressed splenocyte proliferation, T-cell secretion of IL-2 and IL-3, [38] and pro-inflammatory monokine production (Tables 3 and 4) . Indeed this appears to be similar to the action of glucocorticosteroids after LPS challenge [24, 27, 33, 391 . On the other hand, AED did not suppress any of these aspects of immune function. Furthermore, Padgett et al. [7] reported that AED suppressed the activation of the HPA induced by influenza virus. The suppression of corticosterone levels mediated by AED during the influenza infection correlated with increased production of IFN-7 from antigen-specific T cells and increased survival. In contrast, Dobbs et al. [40] showed that stress-induced elevation of serum corticosterone during influenza infection suppressed IFN-7 production and increased morbidity associated with infection.
Thus the influences of AED clearly differ from those attributed to glucocorticoids and, by inference, to DHEA, because the protective effects of DHEA against bacterial or LPS challenge are mediated in part by its glucocorticoid-like properties which result in suppression of TNF-a. However, AED exerted its protective effect by a different as yet unknown mechanism that did not result in suppression of TNF-a production. Further investigations into the possible use of AED in providing protection against antibiotic-resistant opportunist infections may be warranted.
